Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Free Report) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $8.30.
CGTX has been the subject of several research analyst reports. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital restated a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a research report on Thursday, December 19th. Finally, HC Wainwright boosted their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th.
Read Our Latest Analysis on CGTX
Cognition Therapeutics Price Performance
Institutional Trading of Cognition Therapeutics
Several hedge funds have recently made changes to their positions in the business. CM Management LLC increased its stake in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the last quarter. Sigma Planning Corp boosted its holdings in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Cognition Therapeutics during the 3rd quarter valued at $27,000. 43.35% of the stock is currently owned by hedge funds and other institutional investors.
Cognition Therapeutics Company Profile
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Further Reading
- Five stocks we like better than Cognition Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What Does Downgrade Mean in Investing?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.